Betamethasone Dipropionate Patent Expiration
Betamethasone Dipropionate is Used for treating plaque psoriasis. It was first introduced by Schering Corp Sub Schering Plough Corp
Betamethasone Dipropionate Patents
Given below is the list of patents protecting Betamethasone Dipropionate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Sernivo | US10179137 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9364485 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9433630 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9439911 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9655907 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9775851 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
Sernivo | US9877974 | Topical formulations comprising a steroid | Aug 31, 2030 | Primus Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Betamethasone Dipropionate's patents.
Latest Legal Activities on Betamethasone Dipropionate's Patents
Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 8th Yr, Small Entity | 06 Mar, 2024 | US9433630 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 14 Dec, 2023 | US9364485 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jul, 2022 | US10179137 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Jul, 2021 | US9877974 |
Email Notification Critical
| 26 Apr, 2021 | US10179137 |
Change in Power of Attorney (May Include Associate POA) Critical
| 26 Apr, 2021 | US10179137 |
Correspondence Address Change Critical
| 22 Apr, 2021 | US10179137 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 22 Apr, 2021 | US10179137 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 21 Apr, 2021 | US9877974 |
Change in Power of Attorney (May Include Associate POA) Critical
| 21 Apr, 2021 | US9877974 |
Betamethasone Dipropionate's Family Patents
